Abstract: A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises at least a polyanionic material and at least a source of hydrogen peroxide. The formulation can comprise an ophthalmically active agent for treating or controlling a disease or disorder of the eye.

Abstract: Ophthalmic compositions that comprise 0.1 ppm to 50 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 2 wt. % of an anionic biopolymer; and 0.01 wt. % to 2 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C30alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from C1-C4alkyl; R4 is a C2-C8alkylene optionally substituted with hydroxyl; and Y is CO2? or SO3. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C16alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site.

Abstract: Compositions comprise: (a) a material selected from the group consisting of antihistamines, stabilizers, salts thereof, and combinations thereof; and (b) a vasoconstrictor, decongestant, or a salt thereof, provided when the material consists of an antihistamine or a salt thereof, at least one antihistamine other than ketotifen and salts thereof is present. In certain embodiments, the compositions have a pH maintainable at about 5 or less during storage. The compositions can be used to treat, alleviate or ameliorate ocular allergic conditions.

Abstract: Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, at least a polyol, and a pharmaceutically acceptable carrier, wherein the compositions have pH in the range from about 5 to about 7.5. In some embodiment, the compositions can further include a chelating agent, a buffering system or agent, an organic acid, or combinations thereof.

Abstract: Compositions for relief, treatment, or prevention of a condition of dry eye comprise alginate, a polyol, and a combinations of at least two organic acids or salts thereof, wherein the compositions have pH in the range from about 5 to about 7.5, at least one of the organic acids or salts thereof has a pKa in the range from and 6 to about 10. In some embodiments, the second organic acid or a salt thereof has a pKa that is no more than 1.5 units less than the pH.

Abstract: Contact lens care solutions that are formulated for disinfecting or packaging contact lenses that comprise silver, or for disinfecting or storing contact lenses in contact lens cases that comprise silver.

Abstract: The present invention includes a package for a medicament for treating infectious disease. The package comprises a first vessel and a second vessel. The first vessel contains a solid mixture of a biguanide antimicrobial agent and a polyol. The polyol has a melting point above room temperature. The ratio of biguanide antimicrobial agent to polyol is a maximum of about 1:5 and a minimum of about 1:1000. The solid mixture comprises less than 10 wt. % water based upon its total weight. The second vessel comprises an aqueous diluent. The present invention includes methods of manufacturing the package and methods of treating infection.

Abstract: The present invention is directed to new and improved packaging systems for storing ophthalmic devices such as contact lenses and to methods for packaging such ophthalmic devices with aqueous packaging solutions to improve the comfort of the lens during wear. In particular, the present invention is directed to a packaging system for storing an ophthalmic device in an aqueous packaging solution comprising an anionic polymer and a non-ionic polyol. Such solutions can be retained on the surface of an unused lens for extended periods of time, resulting in surface modification that persists in the eye, which may provide significant improvement in the wetting properties of fresh contact lenses used for the first time and, moreover, even several hours after lens insertion, preventing dryness and improving lubricity.

Abstract: The present invention includes a method of treating inflammation of the eye comprising administering to an eye of a patient suffering from inflammation of the eye, a composition comprising an aqueous solution of alginate having a minimum of about 50% mannuronate residues based upon the total number of saccharide monomeric units.

Abstract: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.

Abstract: An ophthalmic composition that includes an epithelium cell stabilizer component. The epithelium cell stabilizer component may be one or more of diglycine, triglycine, tetraglycine, pentaglycine. The invention is also directed to a method of treating or preventing dry eye comprising administering an effective amount of the ophthalmic composition to the eye.

Abstract: A composition for providing relief to a discomfort of an eye comprises a pharmaceutically acceptable carrier and a material that allows the composition to remain in an ocular environment for an extended period of time. The composition can further comprise an active ingredient selected from the group consisting of anti-allergic agents, anti-inflammatory agents, anti-infective agents, and combinations thereof.

Abstract: A method for cleaning or disinfecting contact lenses comprising providing an ophthalmic composition comprising a quaternary polymer and a primary antimicrobial agent with the proviso that the quaternary polymer is not a cationic cellulosic polymer and is distinct from, and mutually exclusive of, the primary antimicrobial agent.

Abstract: A composition for treating or reducing a dry eye condition or an ophthalmological disorder that has an etiology in inflammation comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The composition can be formulated for topical application, injection, or implantation.

Abstract: An improved pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users. The pharmaceutical formulation comprises at least a polyanionic material and at least a zinc-based compound.

Abstract: A rigid gas permeable lens care composition. The composition includes a disinfecting amount of at least one biguanide antimicrobial agent and a straight chain polyether surfactant based upon PEO-PPO-PEO, PPO-PEO-PPO and combinations thereof. In one embodiment, the straight chain polyether surfactant has an HLB value of less than or equal to 15 and an average molecular weight value of between about 5000 and 7000. Preferably, no rubbing is required to disinfect the rigid gas permeable contact lenses is required. Methods of making and using the same are also described.

Abstract: A method of reducing foam formation and improving odor in ophthalmic solutions, such as multipurpose cleaning and conditioning solutions and contact lens packing solutions. The ophthalmic solutions contain surfactant and aroma compound in an amount effective to decrease foam formation. The aroma compound has a low molecular weight and pleasing smell.

Abstract: Provided herein is a pharmaceutically acceptable composition comprising a biguanide containing antimicrobial agent and an additional antimicrobial agent. The invention further comprises topically administering the pharmaceutically acceptable composition to a patient in need of treatment.